CA2662636C - Compositions de n-acetylcysteine et methodes pour traiter des exacerbations aigues de maladies pulmonaires inflammatoires - Google Patents

Compositions de n-acetylcysteine et methodes pour traiter des exacerbations aigues de maladies pulmonaires inflammatoires Download PDF

Info

Publication number
CA2662636C
CA2662636C CA2662636A CA2662636A CA2662636C CA 2662636 C CA2662636 C CA 2662636C CA 2662636 A CA2662636 A CA 2662636A CA 2662636 A CA2662636 A CA 2662636A CA 2662636 C CA2662636 C CA 2662636C
Authority
CA
Canada
Prior art keywords
acetylcysteine
pharmaceutically acceptable
pharmaceutical composition
nac
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2662636A
Other languages
English (en)
Other versions
CA2662636A1 (fr
Inventor
Rabindra Tirouvanziam
Leonore A. Herzenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CA2662636A1 publication Critical patent/CA2662636A1/fr
Application granted granted Critical
Publication of CA2662636C publication Critical patent/CA2662636C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention porte sur des compositions de N-acétylcystéine et des méthodes de traitement de déséquilibre dinflammation et doxydoréduction dans les exacerbations aiguës de maladie pulmonaire inflammatoire.
CA2662636A 2008-04-15 2009-04-15 Compositions de n-acetylcysteine et methodes pour traiter des exacerbations aigues de maladies pulmonaires inflammatoires Active CA2662636C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4494308P 2008-04-15 2008-04-15
US61/044,943 2008-04-15

Publications (2)

Publication Number Publication Date
CA2662636A1 CA2662636A1 (fr) 2009-10-15
CA2662636C true CA2662636C (fr) 2017-01-24

Family

ID=41180997

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2662636A Active CA2662636C (fr) 2008-04-15 2009-04-15 Compositions de n-acetylcysteine et methodes pour traiter des exacerbations aigues de maladies pulmonaires inflammatoires

Country Status (1)

Country Link
CA (1) CA2662636C (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2741954A1 (fr) * 2008-10-29 2010-05-06 Pacific Therapeutics Ltd. Composition et procede de traitement d'une fibrose
FI3554491T3 (fi) 2016-12-15 2023-04-26 Zambon Spa N-asetyylikysteiini käytettäväksi antibakteerisena aineena

Also Published As

Publication number Publication date
CA2662636A1 (fr) 2009-10-15

Similar Documents

Publication Publication Date Title
US20090192227A1 (en) N-Acetylcysteine Compositions and Methods for Treating Acute Exacerbations of Inflammatory Lung Disease
EP2589381B1 (fr) Compositions pour améliorer ou préserver une fonction de poumons chez un patient souffrant de troubles pulmonaires
EP2453743B1 (fr) Compositions de n-acétyl cystéine et leur utilisation pour améliorer l'efficacité thérapeutique de l'acétaminophène
CA2620123C (fr) Methodes de traitement et de surveillance de l'inflammation et du desequilibre d'oxydoreduction dans la mucoviscidose
US20220062203A1 (en) N-Acetylcysteine Amide (NACA) and (2R,2R')-3,3' disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) for the Prevention and Treatment of Radiation Pneumonitis and Treatment of Pulmonary Function in Cystic Fibrosis
CN115531388B (zh) 治疗结核病的药物组合物
JP2004531539A (ja) 非感染性炎症性疾患を治療するためのアジスロマイシンの新規治療適応
JP2009102248A (ja) 血中尿酸を急速に低減させるための医薬組成物およびパッケージならびに血中尿酸を急速に低減させるためのアンセリンの使用
CA2662636C (fr) Compositions de n-acetylcysteine et methodes pour traiter des exacerbations aigues de maladies pulmonaires inflammatoires
WO2021252378A1 (fr) Prévention ou traitement de la covid-19
US20100158857A1 (en) Compositions and methods for the inhibition of endothelial nitric oxide synthase activity
CA3144374A1 (fr) Traitement comprenant des inhibiteurs de sglt, par exemple des inhibiteurs de sglt 1/2
WO2012100365A1 (fr) Utilisation d'un extrait sec standardisé de feuilles de buddleja globosa hope, bg-126, pour le traitement ou la prévention de troubles gastro-intestinaux causés par un traitement à la nitrofurantoïne et autres antimicrobiens
KR20230018474A (ko) 급성 호흡 곤란 증후군, 천식, 또는 알러지성 비염을 치료하기 위한 제형 및 방법
CN108324712A (zh) 维生素c在制备用于治疗和预防结核病的药物中的用途
US20070021508A1 (en) Method for treatment of Helicobacter pylori infection and/or an associated disease
WO2021209620A1 (fr) Inhibiteurs de protéases à cystéine destinés à être utilisés dans la prévention et/ou le traitement d'un coronavirus
RU2817933C1 (ru) Способ лечения атеросклеротических изменений сердечно-сосудистой системы с целью замедления ее старения
CN115551505B (zh) 使用选择性s1r激动剂治疗病毒性感染、疾病或病症
US20080076796A1 (en) Methods and Compositions for the Treatment of Alcoholism and Alcohol Dependence
KR20190044552A (ko) 호흡기 질환 예방 및 치료용 약학 조성물
Dekhuijzen N‐Acetyl Cysteine and Cytoprotective Effects against Bronchopulmonary Damage: From In vitro Studies to Clinical Application
Mahalanobish et al. Chronic Obstructive Pulmonary Disease: Molecular Basis of Pathogenesis and Targeted Therapeutic Approaches
Mahalanobish et al. and Targeted Therapeutic Approaches
EP4364719A1 (fr) Composition pharmaceutique orale pour prévenir et/ou traiter des maladies des tissus mous et durs qui entourent la dent dans la cavité buccale

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140116

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20251015

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251107